Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 921 results for "mylan"

Billionaire Investor Dumps Teva Stock

As Teva fights to acquire an unwilling Mylan, billionaire investor George Soros' Fund Management has sold off all its Teva shares. The fund sold off all of its $279.5M investment in Teva.The Soros Fund contiues to hold stock in other drugmakers, ... Pharmaceutical Manufacturing Magazine, 11 hours ago
[x]  

477 images for mylan

Big Law Business, 11 hours ago
I Stock Analyst, 1 day ago
Business Today India, 2 weeks ago
Pittsburgh Post-Gazette, 2 weeks ago
KVAL 13, 2 weeks ago
Fidelity Brokerage Services LLC, 2 weeks ago
European Pharmaceutical Review, 2 weeks ago
Bio Spectrum Asia, 2 weeks ago
Irish Times, 2 weeks ago
Pittsburgh Post-Gazette, 3 weeks ago
Reuters

Noven Pharmaceuticals and Hisamitsu file patent litigation against Mylan

Noven Pharmaceuticals Inc. and Hisamitsu Pharmaceutical Co., Inc. have filed a patent litigation against Mylan N.V. and its subsidiaries, Mylan Pharmaceuticals Inc. and Mylan Technologies Inc., regarding the filing of an abbreviated new drug ...
 Individual.com1 day ago Mylan settles Viagra patent litigation with Pfizer  Business Standard1 month ago
Money Control

Mylan launches Gilead's hepatitis C drug in India

Mylan N.V., a generic pharmaceutical company, has announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched Gilead Sciences's Sovaldi, which is indicated for the treatment of chronic hepatitis C infection, in India. In ...
 Individual.com3 days ago Mylan Launches Gilead Sciences' Sovaldi® Tablets in India  4 Traders1 week ago Mylan Launches Generic Seasonale® Tablets  4 Traders1 week ago Mylan launches hepatitis-C Sovaldi tablets in India  Economic Times2 weeks ago
[x]  

Mylan's Rs 5,168 crore deal to buy Strides unit gets cabinet nod

New Delhi : The government today cleared the Rs 5,168 crore deal of US-based Mylan Inc for acquiring Bangalore-based pharma firm Agila Specialties, a subsidiary of Strides Arcolab. The decision was taken at a meeting of the Cabinet ...
 NDTV Profit6 days ago
MSN India

A Stichting and What It Can Do for Mylan

In April, Teva Pharmaceuticals Ltd. made a $40 billion offer for Mylan NV, which Mylan sharply rebuffed. The company has been upfront about the fact that, in weighing a bid, its shareholders aren't its only priority; rather, its
 Yahoo! UK and Ireland1 week ago Mylan rejects drug company Teva's $40.1 billion buyout offer  Times of India3 weeks ago Mylan rejects Teva's $40 billion offer  MSN India3 weeks ago Mylan rejects Teva's $40.1 bn buyout offer, but leaves door open  Economic Times3 weeks ago
[x]  
Reuters

Why Teva Pharmaceutical Industries (TEVA) Rejected Perrigo Company To Go After Mylan NV

Teva Pharmaceutical Industries Ltd (ADR) ( NYSE:TEVA ) reportedly had a chance to acquire Perrigo Company ( NYSE:PRGO ) a few months ago, according to information provided to Globes by people familiar with the matter. The bankers hired by Perrigo, ...
 Bidness Etc1 week ago Report: Mylan spurned Teva offer, now exec says it might buy Teva  Philadelphia Business Journal1 week ago Mylan Chairman Tells Investors He Would Consider Buying Rival Teva  BioSpace1 week ago Recap: Teva Pharmaceuticals (TEVA) Plans Raised Bid For Mylan NV (MYL)  Mr Top Step1 week ago

Mylan, Teva push on despite rejections from Perrigo

Israel's generics giant Teva restated its interest in buying Mylan despite a blistering rejection from Mylan earlier this week. NEW YORK: Suitors in the generic drug industry's big consolidation push signaled Wednesday they would keep fighting for deals, even ...
 Economic Times3 weeks ago Big pharma deals: Mylan raises bid for Perrigo to $35.6 billion  Economic Times3 weeks ago Big deals: Mylan, Teva push on despite rejections  Economic Times3 weeks ago Big pharma deals: Mylan, Teva push on despite rejections  Economic Times3 weeks ago
Business Standard

Mylan launches anti-hepatitis drug in India

Drug is used in treatment of chronic hepatitis C infection Dasarath Reddy | Hyderabad May 4, 2015 Last Updated at 11:20 IST Mylan Pharmaceuticals, the Indian subsidiary of US generics pharmaceutical major Mylan NV, has launched anti-hepatitis drug Sovaldi ...
 Business Standard2 weeks ago Mylan launches Generic Sofosbuvir Tablets in India  India Infoline3 weeks ago Mylan launches generic hepatitis C drug MyHep in India  Business Standard4 weeks ago Mylan launches hepatitis C drug MyHep in India  Economic Times4 weeks ago

Mylan to invest $5 billion in AP to expand presence

HYDERABAD: Global pharmaceutical major Mylan is considering strengthening its footprint in Andhra Pradesh with an additional investment of USD 5 billion (Rs 31,000 crore), a top company official said today. A delegation of the US-India Business Council ...
 Economic Times1 month ago Mylan to invest $5 bn in Andhra Pradesh to expand presence  Business Standard1 month ago
Business Standard

Biocon-Mylan Programs Make Progress: PEG-G-CSF and Adalimumab enter Phase 3 clinical trials; Patient recruitment for one Insulin Glargine Phase 3 study completed

Release date- 08052015 - Biocon, Asia's premier biotechnology company, announced today that it has made clinical progress in its partnered programs with Mylan. The partnership has a strong portfolio of generic insulin analogs and biosimilars ...
 Pharmacy Choice1 week ago Biocon begins phase-3 trials for cancer drug  Business Standard2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - mylan
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less